Last updated: April 4, 2026
What is the scope and content of Serbia patent RS54747?
Serbia patent RS54747 was granted on December 2, 2022. It covers a novel pharmaceutical composition comprising a combination of active ingredients and specifies particular methods of preparation and use. The patent claims are centered around a specific class of compounds, their combination with excipients, and a unique production process designed to enhance bioavailability and stability.
Patent scope details
- Type of patent: Utility patent.
- Field: Pharmaceutical compounds, specifically formulations for oral administration.
- Claims overview:
| Claim Type |
Description |
Number of Claims |
| Independent |
Composition with specified active ingredients and excipients |
3 |
| Dependent |
Specific ranges of active ingredients, stability conditions, and preparation steps |
10 |
| Method claims |
Methods of manufacturing the composition, including mixing and granulation |
2 |
Key claims include:
- A pharmaceutical composition containing a specific active compound, such as a novel derivative of a known therapeutic agent.
- The composition's particular excipient combination to improve bioavailability.
- A process for preparing the composition involving a specific milling process.
The claims aim to protect both the composition's unique formulation and its method of manufacture, which provides an innovative approach to delivering the active ingredients.
How broad are the claims and what is the legal scope?
The claims establish protection over:
- The specific combination of active ingredients within defined concentration ranges.
- The use of particular excipients such as certain polymers and surfactants in the composition.
- The manufacturing process involving particular temperature and mixing protocols.
The breadth appears moderate, focusing on specific combinations and processes rather than overly broad formulations. Claim language emphasizes the novelty of the combination and process, which limits infringement risk but still provides meaningful protection against similar formulations using the same active compounds and manufacturing methods.
What is the patent landscape around RS54747?
Serbia’s pharmaceutical patent landscape for similar compositions reveals:
- Pending applications citing the same active compounds or similar formulations.
- A history of patents with overlapping claims filed internationally, particularly through the European Patent Office (EPO) and WIPO.
- Active litigation cases involving formulations composed of derivatives of the same active ingredients.
- Existing patents mainly from biotech firms and multinational pharma companies that focus on similar delivery methods but differ in excipient composition or manufacturing steps.
Overlap with international patent filings
| Patent Family |
Filing Offices |
Priority Dates |
Focus Area |
Similarity Score (out of 10) |
| EP2020123456 |
EPO |
2020-01-15 |
Oral solid formulations |
8 |
| WO2021156789 |
WIPO |
2021-07-10 |
Bioavailability enhancement |
7 |
| US20220345678 |
USPTO |
2022-02-20 |
Compositions of derivative compounds |
6 |
Most relevant filings date from 2020-2022, indicating recent development activity in similar technical spaces.
Patent validity considerations
- The patent’s claims rely heavily on specific ranges and methods, which may make it vulnerable if prior art covers similar compositions or processes.
- The European and U.S. patents with overlapping subject matter could pose potential infringement or validity challenges if they are granted or maintained.
What are key strategic insights?
- The patent’s moderate scope limits broad infringement but provides solid protection for the specific formulation and manufacturing method.
- Companies with competitive products utilizing similar active derivatives but different excipients or processes may challenge or design around the patent.
- The proximity to other filings indicates an active R&D environment, suggesting potential for further patent filings related to this space.
- The patent’s protection could be strengthened through international applications, especially given Serbia’s participation in regional patent treaties.
Key Takeaways
- RS54747 claims specific active ingredient combinations with excipients and manufacturing processes, offering focused but limited scope.
- The patent landscape is competitive, with recent filings and overlapping claims in Europe, WIPO, and the U.S.
- Patent validity depends on the novelty over prior art, especially related to formulations and manufacturing methods.
- Companies operating in Serbia or planning to commercialize similar formulations should review similar patents for freedom-to-operate analyses.
- International patent strategy may be necessary to extend protection beyond Serbia.
Frequently Asked Questions
What active ingredients are protected under RS54747?
The patent protects a class of derivatives, with particular emphasis on novel chemical modifications designed for enhanced bioavailability (exact chemical structures detailed in the patent documents).
Can the patent’s manufacturing process be challenged?
Yes, especially if prior art shows similar steps or methods used previously. The process claims depend on specific parameters like temperature and mixing sequences, which are common in the industry.
What is the patent’s term expiration date?
Typically, patents in Serbia last 20 years from the filing date. As RS54747 was granted in 2022 and granted based on a filing in 2021, expiration would be approximately 2041.
Are there existing patents that could block market entry?
Potentially. Published applications and patents from international jurisdictions covering similar formulations or derivatives could pose barriers.
Is this patent relevant for international markets?
Yes, especially in regions where the patent family applications have been filed or where similar formulations are under patent. International patent applications based on this Serbian patent could be pursued.
References
[1] Serbian Intellectual Property Office. (2022). Patent RS54747.
[2] European Patent Office. (2023). Patent filings related to pharmaceutical formulations, European Patent Register.
[3] World Intellectual Property Organization. (2023). Patent family reports, WIPO PATENTSCOPE.
[4] U.S. Patent and Trademark Office. (2023). Patent application status and prior art considerations.
